Clinical trial
Study of Letrozole Plus Tipifarnib or Placebo in the Treatment of Advanced…
NCT00050141 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry · Completed
Key facts
| NCT number | NCT00050141 |
|---|---|
| Title | Study of Letrozole Plus Tipifarnib or Placebo in the Treatment of Advanced Breast Cancer |
| Official title | A Randomised, Blinded, Phase 2 Study of Letrozole Plus the Farnesyl Transferase Inhibitor ZARNESTRA TM (R115777) and Letrozole Plus Placebo in the Treatment of Advanced Breast Cancer After Antiestrogen Therapy. |
| Lead sponsor | Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | ZARNESTRA, tipifarnib, R115777 |
| Enrollment | 121 |
| Start date | Sep 1, 2002 |
| Primary completion | Oct 1, 2005 |
| Completion | Jan 1, 2008 |
| First posted | Nov 28, 2002 |
| Last update posted | Feb 1, 2013 |
| Countries | Belgium, France, Netherlands, Russia, United Kingdom, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: